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INTRODUCTION
Neonatal alloimmune neutropenia (NAN) occurs when a
mother becomes sensitized to a foreign antigen of paternal
origin that is present on fetal granulocytes (1, 2). These fetal
granulocyte antigens sensitize the mother and provoke anti-
body production. Moreover, immunoglobulin G (IgG) anti-
body readily crosses the placenta and destroys fetal granulo-
cytes by providing opsonic assistance to splenic macrophages
(2). Neutropenia is typically self-limiting and last for several
weeks, but can persist for as long as 6 months. During this
period, neonates are at high risk of developing infections (2,
3). In NAN, symptomatic infants often present with delayed
separation of the umbilical cord, skin infections, otitis media,
or pneumonia within the first 2 weeks of life (2), and whereas
most infections are mild, severe sepsis is known to occur. The
mortality rate in NAN has been reported to be about 5% (2),
and the severity of neutropenia is influenced by antibody titer
and IgG subclass (1, 2). A wide variety of antigenic targets
have been identified in NAN, but the antigens most com-
monly involved are human neutrophil antigen-1a (HNA-1a),
HNA-1b, and HNA-2a (2, 4). Diagnosis of immune neu-
tropenia is dependent on the demonstration of granulocyte-
specific antibody in serum, which can be performed using (2,
5, 6) the granulocyte agglutination test (GAT), the granulo-
cyte immunofluorescence test (GIFT), the monoclonal anti-
body immobilization of granulocyte antigens assay (MAIGA),
and the mixed passive hemagglutination assay (MPHA). In
the present study, MPHA was used to detect granulocyte-spe-
cific antibody. 
Here we report a neonate with neonatal alloimmune neu-
tropenia associated with anti-human neutrophil antigen-1a
(anti-HNA-1a) antibody. 
CASE REPORT
Clinical and laboratory history
A female neonate was born from a healthy 30-yr-old, gravi-
da 1, para 1 mother, whose first child was born without spe-
cific problems. The neonate, weighing 2,810 g, was born at
gestation week-36 by spontaneous vaginal delivery. The baby
appeared to be healthy and physical examinations revealed no
abnormality. However, routine laboratory examinations on
day 1 showed severe neutropenia: total white blood cell count
(WBC) 7,200/ L, and absolute neutrophil count (ANC) 430/
L. Other hematological and biochemical profiles were within
normal limits. Blood and urine cultures were obtained and
prophylactic gentamicin and ampicillin/sulbactam were ad-
ministered for potential sepsis. On days 3 and 5, complete
blood counts showed persistent severe neutropenia (ANC 320/
L and 200/ L, respectively). On day 6, recombinant human
granulocyte colony-stimulating factor (rhG-CSF) therapy was
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A Case of Neonatal Alloimmune Neutropenia Associated with 
Anti-Human Neutrophil Antigen-1a (HNA-1a) Antibody 
Neonatal alloimmune neutropenia (NAN) is an uncommon disease of the newborn
provoked by the maternal production of neutrophil-specific alloantibodies, whereby
neutrophil IgG antibodies cross the placenta and induce the destruction of fetal neu-
trophils. Affected newborns are usually identified by the occurrence of bacterial infec-
tions. The most frequent antigens involved in NAN are the human neutrophil antigen-
1a (HNA-1a), HNA-1b, and HNA-2a. We report a neonate who was delivered at 36
weeks and had a severe neutropenia but who responded well to recombinant human
granulocyte colony-stimulating factor (rhG-CSF). Anti-HNA-1a antibody was identi-
fied by mixed passive hemagglutination assay in both the sera of the baby and the
mother. The baby had HNA-1a and HNA-1b but the mother had only HNA-1b on
granulocytes. This is the first Korean report of NAN in which the specificity of the
causative antibody was identified.
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started at 10  g/kg/day. After 3 days of therapy, ANC incre-
ased to 8,100/ L (day 10) and rhG-CSF therapy was stopped.
Blood and urine were sterile and thus to further evaluate neu-
tropenia, blood samples were obtained from the patient and
mother. Genotyping of granulocytes from patient and moth-
er, and serum assays for granulocyte-specific antibody were
performed. Polymerase chain reaction with sequence-specif-
ic primers (PCR-SSP) was used for the granulocyte typing,
and showed that the patient’s granulocytes had both HNA-
1a and HNA-1b but that the mother’s had HNA-1b only.
Patient’s and maternal sera were found to contain granulocyte-
specific antibodies against HNA-1a by mixed passive hemag-
glutination assay (MPHA). Antibodies were detected at 1:8
(patient) and 1:16 (mother) dilutions, respectively. Patient
ANC peaked at 17,560/ L on day 12, and subsequently fell
to more than 2,000/ L (Fig. 1). She was discharged home at
21 days of age. 
HNA-1a and HNA-1b genotyping 
DNA was isolated from blood samples of the patient and
her mother using QIAamp DNA Blood Mini kit (QIAGEN
GmbH, Hilden, Germany). To type HNA-1a and -1b, PCR-
SSP was performed according to the protocols described by
Bux et al. (7). NA1 (5′ CAGTGGTTTCACAATGAA3′ ) was
used as a sense primer specific for HNA-1a (FCGR3B*1) and
NA2 (5′ CAATGGTACAGCGTGCTT3′ ) for HNA-1b (FC
GR3B*2). NA reverse (5′ ATGGACTTCTAGCTGCAC3′ )
was used as an antisense primer common to HNA-1a and
HNA-1b. And, for internal control purposes, two primers
(HGH I and HGH II) amplifying a 439 bp fragment of the
human growth hormone gene (HGH) were used. Amplifica-
tion was performed in a 20- L reaction mixture containing
the following: 0.2  M of each primer; 200  M (each) dATP,
dCTP, dTTP, and dGTP; 10 mM Tris-HCl (pH 9.0), 1.5 mM
MgCl2, 40 mM KCl; 1 unit of Taq polymerase (Perkin-Elmer,
Cetus, CT, U.S.A.); and 1  L of DNA sample. Thirty cycles of
amplification were preformed in a DNA thermal cycler (Ge-
neAmp PCR 9600 system, Perkin-Elmer, Cetus, CT, U.S.A.).
Each cycle consisted of the followings: predenaturation at 95
℃ for 3 min, 30 amplification cycles of (denaturation at 95
℃for 1 min, primer annealing at 58℃for 1 min, and exten-
sion at 72℃for 1 min). The sizes of the amplified DNA frag-
ments were 141 bp and 219 bp for the HNA-1a and HNA-
1b genes, respectively (7). The mother had no HNA-1a and
the patient had both HNA-1a and HNA-1b (Fig. 2). 
Granulocyte-specific antibody test using MPHA 
To detect granulocyte-specific antibodies, sera from patient
and mother were tested using MPHA. Extracted granulocyte
antigens from 6 voluntary donors, whose granulocyte types
were known, were coated in the well of U-bottomed micro-
plates (Maxisorp Lockwellmodule, Nunc, Roskide, Denmark).
The negative control serum used was derived from a healthy
male donor with no history of transfusion, and positive con-
trol sera (anti-HNA-1a, anti-HNA-1b, and anti-HNA-2b)
and indicator cells (sheep RBCs coated with rabbit F (ab′ )2
anti-human IgG) were provided by Prof. K. Takahashi (The
University of Tokyo, Tokyo, Japan). The tests were performed
according to the protocols described by Araki et al. (5). The
sera of both patient and mother were reactive to the granulo-
cyte antigens of donors 1, 2, 3, 5, which all contained HNA-
1a (Fig. 3). To differentiate human leukocyte antigen (HLA)
antibody and granulocyte-specific antibody, granulocyte anti-
gens coated microwells were treated with 0.8 M chloroquine
solution (5). After the chloroquine treatment, the sera were
reactive in the same pattern (Fig. 3). Both patient and mater-
nal serum were diluted, and anti-HNA-1a antibody reactiv-
ity persisted to dilutions of 1:8 and 1:16, respectively. 
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Fig. 1. Absolute neutrophil counts of patient during the day of life.
Each arrow represents a single dose of rhG-CSF administered.
rhG-CSF
Fig. 2. NA-1a and -1b genotyping by PCR-SSP. Lane 3 shows a
DNA ladder marker (Bioneer, Daejeon, Korea). The amplification
products (439 bp) of the internal control (the HGH gene) is present
in every lane. The genotype can be deduced from the presence
of amplification products that are specific for HNA-1a (FCGR3B*1,
141 bp) and HNA-1b (FCGR3B*2, 219 bp). The patient had both
HNA-1a and HNA-1b, but mother had HNA-1b (lane 5) only.
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DISCUSSION
Granulocyte antigens-NA1 (HNA-1a), NA2 (HNA-1b),
and NB1 (HNA-2a) were first characterized by Lalezari and
Radel in 1974 (8) and the human neutrophil antigens (HNA)
system was proposed by Bux in 1999 (9). The HNA nomen-
clature is based on the glycoprotein locations of various anti-
gens and the nomenclature of alleles according to the Guide-
lines of the International Workshop on Human Gene Map-
ping. The HNA system comprises seven antigens, which are
assigned to five glycoproteins (9). 
Antibodies against granulocyte antigens have been impli-
cated in NAN, autoimmune neutropenia, and transfusion
related acute lung injury (6, 10). However, no confirmed clini-
cal report has been issued on these disorders in Korea, since
the techniques required to identify granulocyte-specific anti-
bodies are complicated. Here we used the MPHA technique
to detect granulocyte-specific antibodies. Patient’s serum sam-
ples were tested against a panel of granulocytes from six donors
with known phenotypes to identify antibody specificities.
However, the presence of HLA antibodies can make the detec-
tion of granulocyte-specific antibodies difficult (6). To remove
HLA from extracted granulocyte antigens, we treated anti-
gens with chloroquine. Subsequently, the panel of extracted
granulocyte antigens did not react with anti-HLA antibody.
This is the first case of NAN due to anti-HNA-1a in Korea.
The mother was a HNA-1b-homozygote and her baby was a
HNA-1a/-1b heterozygote. The mother might have been sen-
sitized with HNA-1a antigen during her first pregnancy, and
this may have provoked the production of anti-HNA-1a anti-
body. HNA-1a and -1b are biallelic granulocyte antigens and
are located on Fc RIIIb. 
The frequencies of HNA-1a and -1b differ significantly in
Caucasian and Asians (11, 12). HNA-1a and -1b gene frequ-
encies have been reported to be 0.35 and 0.65 in Caucasians,
0.69 and 0.31 in Chinese, and 0.52 and 0.48 in Koreans, res-
pectively (7, 11-13). Thus, HNA-1b homozygote pregnan-
cies are more common in Caucasians than in Asians. In Cau-
casians, anti-HNA-1a antibodies are the most commonly de-
tected in NAN (14, 15). However, no data is available on
NAN antibody frequencies in Asians. However, in view of
the reported HNA-1a and -1b gene frequencies, fetomater-
nal granulocyte mismatches due to HNA-1b may be more
common in Asians than in Caucasians, and anti-HNA-1b
antibodies may be more common in Asians. Zupanska et al.
reported fetomaternal granulocyte antigen mismatches (HNA-
1a and -1b only) in 19.6% of mothers, and granulocyte-spe-
cific antibodies in 4.5% of fetomaternal incompatible moth-
ers (alloimmunization in 0.9% of mothers). The authors sug-
gested that NAN related to the two antigens (HNA-1a and
-1b) occurs in less than 0.1% and severe NAN in 0.06% (14).
However, similar information is unavailable on other antigens
implicated in NAN, and a much higher frequency of NAN
would be expected based on considerations of all possible feto-
maternal granulocyte antigen mismatches. Estimates of the
frequency of NAN can vary widely and range from 0.2 to 20
% (1, 2), but such estimates are not easily compared because
of differences in study designs, period, and the different lab-
oratory methods used. A wide variety of antigens including
the HNA system and HLA have been identified in NAN
(1, 2, 16). However, the antigens involved are unidentified
in almost half of all cases (2, 16), and nearly a half of all cases
are mediated by antibodies that bind to HNA-1a, -1b, or -2a
(2, 15). Our unpublished data suggest that the incidence of
alloimmunization against granulocyte antigens is 3.5% (6/170)
in mothers (HNA-1a and -1b, 2.4% [4/170]), and that the
incidence of NAN is more than 0.07% (1/1,500) among Kore-
an newborns. 
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